Oral selumetinib (AstraZeneca) reduces tumor volume in children with inoperable plexiform neurofibroma, benign tumors of peripheral nerves related to neurofibromatosis type 1 (NF1), with acceptable ...

Benign tumors, neurofibromas can arise anywhere along a nerve fiber and usually involve nerves in or near the skin. The tumors are populated by Schwann cells, fibroblasts, mast cells, and vascular ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

Cred: SpringWorks Therapeutics. Mirdametinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2. Gomekli is the first medication approved for both adult and pediatric patients with ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

Neurofibromatosis type 1 (NF1) is a rare genetic condition that affects how certain nerve cells grow and develop. Children with NF1 can have small growths on or under the skin called neurofibromas.

Figure 1 (A) Clinical picture, (B) Usg showing intramuscular heterogenous lesion arising from sciatic nerve, (C) MRI showing heterogeneously isointense mass measuring 12.8 × 6.6 × 3.8 cm with features ...

Panelists discuss key findings supporting the use of MEK inhibitors, such as selumetinib, in treating NF1-associated plexiform neurofibromas, emphasizing its impact on clinical decision-making, ...

Dr. Robert (Bob) Kesterson is Professor of Cancer Precision Medicine and Director of the Genetically Engineered Models, or GEMS, core facility at the Pennington Biomedical Research Center.